Related Experiment Video
Updated: May 22, 2026
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
Sorafenib increases 18-FDG colic uptake: demonstration in patients with differentiated thyroid cancer
Renaud Ciappuccini1, Géraldine Trzepla, Natacha Heutte
1Departments of Nuclear Medicine and Thyroid Unit, Centre François Baclesse, 3 Avenue Général Harris - BP 5026, Cedex 05, Caen, 14076, France. r.ciappuccini@baclesse.fr.
Background:
To assess 18-fluorodeoxyglucose (FDG) bowel uptake in patients with differentiated thyroid cancer (DTC) treated with sorafenib.
Findings:
Visual (5-point scale) and high maximum standard uptake value (SUVmax) semi-quantitative analyses were conducted in 63 positron emission tomography (PET) studies performed in patients on sorafenib (group 1, n = 20), in a control group (group 2, n = 28) and in patients on sunitinib or vandetanib (group 3, n = 15).Moderate or high and diffuse bowel uptake (grade 4 or 5) was observed in 90% of the PET scans of group 1 versus none in group 2. Only 20% of PET scans in group 3 were scored grade 4. SUVmax values were significantly higher for all colic segments in group 1 than in group 2 (P < 0.0001) or 3 (P < 0.0004). This uptake pattern appeared rapidly (one month) and disappeared after sorafenib withdrawal.
Conclusions:
FDG uptake is increased in the colon of DTC patients treated by sorafenib.
